CA
DFTX

Continuum Advisory’s Definium Therapeutics DFTX Stock Holding History

Continuum Advisory’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10K Buy
+213
New +$5.26K ﹤0.01% 1255
2025
Q2 		– Sell
-239
Closed -$1.4K – 1130
2025
Q1 		$1.4K Hold
239
– – ﹤0.01% 1446
2024
Q4 		$1.66K Hold
239
– – ﹤0.01% 1477
2024
Q3 		$2K Buy
239
+219
+1,095% +$1.52K ﹤0.01% 1427
2024
Q2 		$144 Hold
20
– – ﹤0.01% 1678
2024
Q1 		$182 Buy
+20
New +$114 ﹤0.01% 1670

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Continuum Advisory's DFTX Position: Q2 2026 in Review

Continuum Advisory opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 213 shares worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #1255 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in DFTX as recently as Q1 2025.

Continuum Advisory first reported a position in DFTX in Q1 2024 and has held it in 6 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Continuum Advisory held 213 shares of Definium Therapeutics worth $10K as of Q2 2026.
  • Definium Therapeutics was a new Continuum Advisory position in Q2 2026.
  • Definium Therapeutics made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1255 holding.
  • Continuum Advisory first reported a position in Definium Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.